Literature DB >> 22291080

Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?

Ignacio Garrido-Laguna, Filip Janku.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22291080     DOI： 10.1200/JCO.2011.40.6538

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Epidemiology and therapies for metastatic sarcoma.

Authors:  Ernest K Amankwah; Anthony P Conley; Damon R Reed
Journal:  Clin Epidemiol       Date:  2013-05-16       Impact factor: 4.790

2.  A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcoma.

Authors:  Claire F Verschraegen; Sujana Movva; Yongli Ji; Berndt Schmit; Robert H Quinn; Ben Liem; Therese Bocklage; Monte Shaheen
Journal:  Cancers (Basel)       Date:  2013-04-11       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.